Sarasota-based INVO Bioscience, Inc. (IVOB), a US publicly-traded medical device company that was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, will exhibit at the 20th World Congress of the International Society for In-Vitro Fertilization (ISIVF) on October 24-26, 2019 in Barcelona, Spain at booth #15. INVO’s presentation: “Immediate intracytoplasmic sperm injection (ICSI) followed by 5-day intravaginal culture: Single-center outcomes using a sequential letrozole–gonadotropin minimal stimulation protocol.” Dr. Hammond and her team have developed an affordable IVF program utilizing INVOcell to improve access to care with patients traveling to her program from across the United States for treatment.
Dr. Hammond stated, “I am humbled to have the opportunity to serve patients who could have otherwise never afforded to do IVF. Our minimal ovarian stimulation and INVOcell have greatly improved access to care.”
The 20th World Congress of in-Vitro Fertilization is a professional symposium organized by the International Society for In Vitro Fertilization (ISIVF) featuring a breakthrough scientific program on topics within the field of in vitro fertilization of human oocytes (IVF) and various forms of Assisted Reproductive Technology (ART) for the prevention and treatment of infertility and other indicated conditions. For more information please visit, https://www.isivf2019.com/.
IVOB is a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility. Their solution, the INVO® Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Their lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care. For more information, please visit http://invobioscience.com/.
To learn more about INVO Bioscience (IVOB) and to track its progress daily, please the INVO Bioscience Dedicated Company Page by clicking here.